Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
SSEA-1 Antibody (FUT4/815) - IHC-Prediluted, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP248370
Description
SSEA-1 Monoclonal specifically detects SSEA-1 in Human, Mouse, Rat samples. It is validated for Immunohistochemistry, Immunohistochemistry-Paraffin.Specifications
SSEA-1 | |
Monoclonal | |
Unconjugated | |
10mM PBS and 0.05% BSA with 0.05% Sodium Azide | |
Mouse | |
Protein L or PEG purified | |
RUO | |
Primary | |
CD15 plays a role in mediating phagocytosis, bactericidal activity, and chemotaxis. It is present on >95% of granulocytes including neutrophils and eosinophils and to a lesser degree on monocytes. In addition, CD15 is expressed in Reed-Sternberg cells and some epithelial cells. CD15 antibody is very useful in the identification of Hodgkin s disease. CD15 is occasionally expressed in large cell lymphomas of both B and T phenotypes which otherwise have a quite distinct histological appearance. | |
Store at 4C. | |
IgM κ |
Immunohistochemistry (Paraffin) | |
FUT4/815 | |
Immunohistochemistry-Paraffin | |
alpha-(1,3)-fucosyltransferase, CD15, EC 2.4.1, EC 2.4.1.-, EC 2.4.1.65, ELAM-1 ligand fucosyltransferase, ELFT, FCT3AELAM ligand fucosyltransferase, Fucosyltransferase 4, fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific), Fucosyltransferase IV, fucT-IV, FUC-TIV, FUTIV, Galactoside 3-L-fucosyltransferase, Lewis X, LeX, SSEA-1, stage-specific embryonic antigen 1 | |
Purified human SSEA-1 (Uniprot: P22083) | |
7 mL | |
Cellular Markers, Embryonic Stem Cell Markers, Endothelial Cell Markers, Hematopoietic Stem Cell Markers, Immunology, Pancreatic Stem Cell Markers, Stem Cell Markers, Stem Cells | |
2526 | |
Human, Mouse, Rat | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction